|
rs1799793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC2-rs1799793-AA genotype correlated with ER+ and PR+ breast cancer.
|
29544444 |
2018 |
|
rs11615
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs1800975
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs2228001
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs2976392
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Therefore, among Chinese Han women, the PSCA rs2294008, rs2978974, and rs2976392 minor alleles are associated with increased breast cancer risk especially in progesterone receptor positive breast cancer patients, with breast cancer risk in postmenopausal women, and with high lymph node metastasis risk, respectively.
|
27050280 |
2016 |
|
rs2978974
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Therefore, among Chinese Han women, the PSCA rs2294008, rs2978974, and rs2976392 minor alleles are associated with increased breast cancer risk especially in progesterone receptor positive breast cancer patients, with breast cancer risk in postmenopausal women, and with high lymph node metastasis risk, respectively.
|
27050280 |
2016 |
|
rs50872
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs1408080623
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of this study was to evaluate the association of CYP2D6*10 (c.100C>T and c.1039C>T), OATP1B1 A388G, and OATP1B1 T521C polymorphisms with overall survival (OS) for hormone receptor (estrogen receptor or progesterone receptor)-positive tumors (ER+/PR+) breast cancer patients after adjuvant tamoxifen (TAM) therapy.
|
25701109 |
2015 |
|
rs4149056
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of this study was to evaluate the association of CYP2D6*10 (c.100C>T and c.1039C>T), OATP1B1 A388G, and OATP1B1 T521C polymorphisms with overall survival (OS) for hormone receptor (estrogen receptor or progesterone receptor)-positive tumors (ER+/PR+) breast cancer patients after adjuvant tamoxifen (TAM) therapy.
|
25701109 |
2015 |
|
rs4849887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Statistically significant differences were detected with the association of rs6828523 (4q34.1/ADAM29) with ER-positive breast cancer (P = 1.27 × 10(-3)) and the association of rs4849887 (2q14.2) with PR-positive breast cancer (P = 1.29 × 10(-3)).
|
25007960 |
2014 |
|
rs6828523
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Statistically significant differences were detected with the association of rs6828523 (4q34.1/ADAM29) with ER-positive breast cancer (P = 1.27 × 10(-3)) and the association of rs4849887 (2q14.2) with PR-positive breast cancer (P = 1.29 × 10(-3)).
|
25007960 |
2014 |
|
rs10069690
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Index SNPs in five loci were replicated, including three associated with ER-/PR- breast cancer (TERT rs10069690 in 5p15.33, rs704010 in 10q22.3, and rs8170 in 19p13.11): per allele ORs were 1.29 [95% confidence interval (CI) 1.04-1.59], P = 0.02, 1.52 (95% CI 1.12-2.08), P = 0.01, and 1.30 (95% CI 1.01-1.68), P = 0.04, respectively.
|
23136140 |
2013 |
|
rs362962
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs362962 TT genotype also associated with risk of estrogen receptor or progesterone receptor positive breast cancer.
|
23922822 |
2013 |
|
rs8170
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Index SNPs in five loci were replicated, including three associated with ER-/PR- breast cancer (TERT rs10069690 in 5p15.33, rs704010 in 10q22.3, and rs8170 in 19p13.11): per allele ORs were 1.29 [95% confidence interval (CI) 1.04-1.59], P = 0.02, 1.52 (95% CI 1.12-2.08), P = 0.01, and 1.30 (95% CI 1.01-1.68), P = 0.04, respectively.
|
23136140 |
2013 |
|
rs2291738
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, both the G/G genotype of rs2291738 and the C/C genotype of rs7302060 were associated with reduced risk of breast cancer among ER- or PR-positive breast cancer cases (OR, 0.46; 95% CI, 0.22-0.97 and OR, 0.36; 95% CI, 0.17-0.78, respectively).
|
22006848 |
2012 |
|
rs614367
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association for rs614367 was specific to estrogen receptor (ER)-positive disease and strongest for ER plus progesterone receptor (PR)-positive breast cancer, whereas the associations for the other three loci did not differ by tumor subtype.
|
22461340 |
2012 |
|
rs7302060
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, both the G/G genotype of rs2291738 and the C/C genotype of rs7302060 were associated with reduced risk of breast cancer among ER- or PR-positive breast cancer cases (OR, 0.46; 95% CI, 0.22-0.97 and OR, 0.36; 95% CI, 0.17-0.78, respectively).
|
22006848 |
2012 |